Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Inclusion Criteria:

   - Patient must have measurable disease

   - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
   between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky
   performance status of >= 50%

   - Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as
   assessed by the enrolling provider

   - All patients must have sequencing results available from a National Cancer Institute
   (NCI) credentialed Designated Laboratory (DL)

   - Patients must have locally advanced or advanced histologically documented solid tumors
   requiring therapy and meet one of the following criteria:

      - Patients must have progressed on at least one line of standard systemic therapy
      OR

      - Patients whose disease has no standard treatment that has been shown to prolong
      overall survival

   - Patient must meet one of the following requirements:

      - Patients 18 years and older who have tumor amenable to minimal risk image-guided
      or direct vision biopsy and must be willing and able to undergo a tumor biopsy to
      obtain samples for research if the patient is to enroll in a ComboMATCH treatment
      trial OR

      - Patients 18 years and older who do not have disease that is biopsiable at minimal
      risk to the patient must confirm availability of an archival tumor tissue
      specimen for submission for research if the patient enrolls to a ComboMATCH
      Treatment Trial. This tumor tissue must meet the following criteria:

         - Tissue must have been collected within 12 months prior to registration to
         the EAY191 Registration Trial

         - Patient must not have had a Response Evaluation Criteria in Solid Tumors
         (RECIST) response (complete response [CR] or partial response [PR]) to any
         intervening therapy after collection of the tissue

         - Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be
         available OR

      - Patients under 18 years old must confirm availability of an archival tumor tissue
      specimen for submission for research if patient enrolls to a ComboMATCH Treatment
      Trial. This tumor tissue must meet the following criteria:

         - Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be
         available

      - NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and
      management instructions. Performance of the mandatory research biopsy or
      submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection
      and submission of the blood specimens for the integrated studies will be
      performed under the consent authority of the specific treatment trial protocol to
      which the patient is registered. No procedures to collect specimens for research
      only are to be performed for patients registered to the EAY191 Registration Trial
      only

   - NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If
   patient is found to not be eligible for the assigned ComboMATCH Treatment Trial,
   indication of ineligibility will trigger re-evaluation and potential assignment to
   another Treatment Trial